Question

Will a small molecule GLP-1-based drug be approved for the treatment of obesity by the FDA or EMA by 2029?

5 comments5

Total Forecasters37

Community Prediction

62%

(56% - 74%)

Make a Prediction

50%

community: 62%

No key factors yetAdd some that might influence this forecast.

Add key factor

Authors:

casens

Opened:

Nov 24, 2021

Closes:

Jan 1, 2029

Scheduled resolution:

Jan 1, 2029

Spot Scoring Time:

Nov 26, 2021

Health & Pandemics

Food and Drug Administration

Will oral semaglutide be approved for the treatment of obesity by the FDA or EMA by 2027?

80%

Will the FDA or EMA withdraw approval of Semaglutide for the treatment of obesity by 2027?

Will the combination of semaglutide and cagrilintide be approved for the treatment of obesity by the FDA or EMA by 2027?

43%

Authors:

casens

Opened:

Nov 24, 2021

Closes:

Jan 1, 2029

Scheduled resolution:

Jan 1, 2029

Spot Scoring Time:

Nov 26, 2021

Health & Pandemics

Food and Drug Administration

Will oral semaglutide be approved for the treatment of obesity by the FDA or EMA by 2027?

80%

Will the FDA or EMA withdraw approval of Semaglutide for the treatment of obesity by 2027?

Will the combination of semaglutide and cagrilintide be approved for the treatment of obesity by the FDA or EMA by 2027?

43%